Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $15.48 and last traded at $15.57, with a volume of 440107 shares trading hands. The stock had previously closed at $14.69.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on the company. Weiss Ratings downgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th. Barclays lifted their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. UBS Group began coverage on shares of Amneal Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $19.00 target price on the stock. Finally, Truist Financial raised their target price on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $15.80.
Read Our Latest Research Report on Amneal Pharmaceuticals
Amneal Pharmaceuticals Price Performance
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.27 EPS for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The business had revenue of $722.52 million for the quarter. Equities research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current year.
Insider Buying and Selling
In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $12.94, for a total value of $450,557.86. Following the transaction, the director directly owned 93,660 shares in the company, valued at $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 17.30% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Assenagon Asset Management S.A. lifted its position in Amneal Pharmaceuticals by 75.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock valued at $47,398,000 after acquiring an additional 1,611,698 shares during the last quarter. Westshore Wealth LLC purchased a new position in shares of Amneal Pharmaceuticals during the third quarter worth about $13,833,000. Morgan Stanley increased its position in shares of Amneal Pharmaceuticals by 37.5% during the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after purchasing an additional 1,315,018 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Amneal Pharmaceuticals by 72.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock valued at $32,405,000 after purchasing an additional 1,069,400 shares during the last quarter. Finally, Penn Capital Management Company LLC purchased a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at about $12,655,000. 31.82% of the stock is owned by hedge funds and other institutional investors.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.
Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.
Featured Stories
- Five stocks we like better than Amneal Pharmaceuticals
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
